Diaccurate welcomes to its Board of Directors Prof. Karine Lacombe, internationally renowned infectious disease specialist and Dr. Catherine George, expert in early drug development

• Professor Karine Lacombe is an international expert in infectious diseases, and brings extensive experience in clinical practice
• Catherine George has over 30 years’ experience in the pharmaceutical industry in the areas of drug safety and translational medecine

Diaccurate, a French biotechnology company developing “sole-in-class” drug candidates in oncology and immunotherapy, announced today the appointment to its Board of Directors of Professor Karine Lacombe, a renowned expert in infectious diseases, specializing in HIV research and drug development, and Catherine George, President of Ipsen Innovation and Pharm Sciences, specializing in toxicology and translational medecine.

“I warmly welcome Karine and Catherine to Diaccurate's Board of Directors,” said Dr. Philippe Pouletty, Chairman of Diaccurate and co-founder and CEO of Truffle Capital. “Their experience, vision and recommendation will be important to guide the preclinical and clinical development of our programs. The entire Board of Directors is delighted to work with Karine and Catherine to support the Diaccurate team in achieving its goals.”

“I am delighted to join Diaccurate’s Board of Directors,” said Professor Karine Lacombe. “I look forward to working with the talented team at Diaccurate. The Company's programs target very promising areas that hold great hope for the patients. The next steps in development will be crucial to confirm their therapeutic potential.”

“I join Diaccurate’s Board of Directors with great enthusiasm,” said Catherine George. “ The Company's dense and innovative pipeline and the expertise in place puts Diaccurate in a good position to successfully advance clinical programs.”